Japan has a high level of global competitiveness in life sciences fostered by sustained efforts and innovation breakthroughs that many researchers in academia, research institutions, and pharmaceutical companies are bringing forward. Our mission is to help such research outcomes to be funded and to catalyze the translation of innovative medicines serving the needs of the patients.

For patients suffering from diseases, for people involved in healthcare such as researchers, medical doctors, and employees of pharmaceutical companies, we contribute to the most promising technology innovations through the hands-on leverage of our deep knowledge of the sector and unique experiences in finance and drug development. 

About us

Fund:                New Life Science I Investment Limited Partnership

Founded:         February 7, 2019

Fund Size:       JPY 10.1 billion yen (Final close at February 6, 2020)

GP:                   New Life Science I LLP

Target:             Biotech

Stage:              Company Creation, Seed, Early, Middle, Later

Company:        Shinsei Capital Partners, Ltd.

Management:  CEO      Manabu Nakamura

                         Director  Yoshiyuki Yamakawa (Chairman, HIBIKI Partners)

                         Director  Nobuyuki Hata (Professor, Graduate Institute for Entrepreneurial Studies)

                         Director  Takahisa Komoda (Senior Managing Executive Officer, SBI Shinsei Bank)

                         Auditor   Fuyuki Kojima (Partner attorney, HIFUMI Law)


July 2004    Shinsei Bank  (current SBI Shinsei Bank) started Pre-IPO investment
                             in Private Equity division

                             Invested in 75 companies over 14 years from 2004 to 2018, and 29 listed

February 2019   Established Shinsei Capital Partners as a carve-out of Life Science
                              Investment Team in Shinsei Corporate Investment